News about "Pharma Manufacturing"

Morepen Laboratories Bags Zero-Observation USFDA Inspection for Fourth Time

Morepen Laboratories Bags Zero-Observation USFDA Inspection for Fourth Time

Morepen Laboratories clears its fourth consecutive USFDA inspection at the Masulkhana facility with zero observations (NIL 483), reinforcing its CDMO strength following a INR 825 crore global manufacturing mandate.

Pharma Manufacturing | 21/04/2026 | By News Bureau

Rusan Pharma Wins Japan PMDA GMP Nod for Two Key Plants

Rusan Pharma Wins Japan PMDA GMP Nod for Two Key Plants

Rusan Pharma secures Japan PMDA GMP approval for its Ankleshwar and Dehradun facilities, covering both API and finished manufacturing dosage units.

Pharma Manufacturing | 21/04/2026 | By News Bureau

Dr Jitendra Singh Lays Foundation for INR 600 Crore Orchid Pharma Project in J&K

Dr Jitendra Singh Lays Foundation for INR 600 Crore Orchid Pharma Project in J&K

Dr Jitendra Singh laid the foundation for an INR 600 crore multinational pharma manufacturing facility in Kathua, highlighting the region’s rising industrial potential and its role in strengthening India’s pharma exports and economic growth.

Pharma Manufacturing | 18/03/2026 | By Akanki 133

Morepen Bags INR 825 Crore Global Deal

Morepen Bags INR 825 Crore Global Deal

Morepen has secured a ?825 crore global deal, marking its expansion into the high-growth Contract Development and Manufacturing Organisation (CDMO) segment.

Pharma Manufacturing | 24/02/2026 | By News Bureau 118

Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery

Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery

Hikal Ltd reported a net loss of INR 5.9 crore in the third quarter of FY26, compared with a profit of INR 17.2 crore in the corresponding quarter last year. Despite the loss, total revenue from operations increased 10.4 per cent year on year to INR 494.3 crore, up from INR 447.7 crore.

Pharma Manufacturing | 16/02/2026 | By Darshana 147

US FDA Clears Anuh Pharma Facility with No Form 483 Observations

US FDA Clears Anuh Pharma Facility with No Form 483 Observations

The Tarapur facility of Anuh Pharma is already an EUGMP/ WHO pre-qualified approved manufacturing facility with nine API’s blocks and two intermediate block with total capacity of 2400 MTPA.

Pharma Manufacturing | 11/02/2026 | By News Bureau 157

FUJIFILM Biotechnologies Enhances UK Manufacturing with Advanced Downstream Purification System

FUJIFILM Biotechnologies Enhances UK Manufacturing with Advanced Downstream Purification System

FUJIFILM Biotechnologies has announced plans to deploy its proprietary downstream purification system at its manufacturing facility in the United Kingdom, aiming to enhance production efficiency and expand biopharmaceutical processing capabilities.

Pharma Manufacturing | 09/02/2026 | By Darshana 110

Akums Secures EU GMP Approval for Two Haridwar Facilities

Akums Secures EU GMP Approval for Two Haridwar Facilities

The approvals follow successful EU-GMP audits of Akums’ two Haridwar manufacturing facilities, with the drug regulator renewing certification for plant I and granting fresh approval to plant II after assessing operations, quality systems, documentation and compliance with EU GMP standards.

Pharma Manufacturing | 23/01/2026 | By News Bureau 195

Pluri and Remedy Cell Expand Partnership with Clinical-Grade Manufacturing Success

Pluri and Remedy Cell Expand Partnership with Clinical-Grade Manufacturing Success

The duo have integrated Remedy Cell’s proprietary manufacturing process into Pluri’s GMP facility, completed GMP training and qualification for Remedy Cell’s manufacturing team, conducted engineering runs to validate process robustness and scalability, and produced multiple clinical-grade batches of Remedy Cell's lead candidate.

Pharma Manufacturing | 23/12/2025 | By News Bureau 142

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.

Pharma Manufacturing | 22/12/2025 | By News Bureau 253


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members